Brigatinib (Alunbrig (R)) - New Option for Crizotinib-pretreated adult Patients with ALK-positive non-small cell Lung Carcinoma (ALK plus NSCLC)

首页> 外文期刊>Oncology research and treatment. >Brigatinib (Alunbrig (R)) - New Option for Crizotinib-pretreated adult Patients with ALK-positive non-small cell Lung Carcinoma (ALK plus NSCLC)

【24h】

Brigatinib (Alunbrig (R)) - New Option for Crizotinib-pretreated adult Patients with ALK-positive non-small cell Lung Carcinoma (ALK plus NSCLC)

机译：Brigatinib（Alunbrig（r）） - 屈服in-preatroped成年患者的新选择ALK阳性非小细胞肺癌（ALK Plus NSCLC）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Oncology research and treatment.》 |2019年第2期|共1页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Brigatinib (Alunbrig (R)) - New Option for Crizotinib-pretreated adult Patients with ALK-positive non-small cell Lung Carcinoma (ALK plus NSCLC) [J] . Oncology research and treatment. . 2019,第1a2期

机译：Brigatinib（Alunbrig（r）） - 屈服in-preatroped成年患者的新选择ALK阳性非小细胞肺癌（ALK Plus NSCLC）
2. Spotlight on brigatinib and its potential in the treatment of patients with metastatic ALK-positive non-small cell lung cancer who are resistant or intolerant to crizotinib [J] . Rohit K Jain, Hongbin Chen Lung Cancer: Targets and Therapy . 2017,第2期

机译：Brigatinib及其对克唑替尼耐药或不耐受的转移性ALK阳性非小细胞肺癌患者的治疗潜力
3. Brigatinib for the treatment of ALK-positive advanced non-small cell lung cancer patients [J] . A. Passaro, A. Prelaj, A. Pochesci, Drugs of today: Medicamentos de actualidad . 2017,第8期

机译：Brigatinib用于治疗ALK阳性晚期非小细胞肺癌患者
4. Enumeration and ALK Investigation of Circulating Tumor Cells in Non-Small Cell Lung Cancer (NSCLC) Patients Using an Effective In Vivo Technology, the GILUPI CellCollector? [C] . Klaus Luecke, Lukasz Gasiorowski, Stefanie Herold, International Molecular Medicine Tri-Conference. . 2015

机译：使用有效的体内技术（Gilupi Cellcollector
5. 4HPR-X radiation mechanisms of interactions in non-small cell lung cancer (NSCLC) cells in vitro. [D] . Nasca, Melita Maria. 2002

机译：4HPR-X辐射在非小细胞肺癌（NSCLC）细胞中相互作用的体外机制。
6. Brigatinib is another treatment option for patients diagnosed with advanced ALK-positive non-small-cell lung cancer who are treatment-naïve or who have progressed on or are intolerant to crizotinib [O] . Barbara Melosky, Parneet Cheema, Geoffrey Liu 2019

机译：对于诊断为未经治疗或对克唑替尼已进展或不耐受的晚期ALK阳性非小细胞肺癌的诊断患者Brigatinib是另一种治疗选择
7. Brigatinib is another treatment option for patients diagnosed with advanced ALK-positive non-small-cell lung cancer who are treatment-naïve or who have progressed on or are intolerant to crizotinib [O] . Barbara Melosky, Parneet Cheema, Geoffrey Liu 2019

机译：Brigatinib是诊断出患有治疗的晚期ALK阳性非小细胞肺癌的患者的另一种治疗选择，或者在蠕动或不耐受肾小序或不耐受

Brigatinib (Alunbrig (R)) - New Option for Crizotinib-pretreated adult Patients with ALK-positive non-small cell Lung Carcinoma (ALK plus NSCLC)

著录项

相似文献

相关主题

期刊订阅